---
type: claim
domain: health
description: "CMS MSSP 2024 results show ACOs outperformed non-ACO groups on depression screening (53.53% vs 44.42%), blood pressure control (71.21% vs 67.82%), and cancer screening while generating $2.48B net savings, defeating the under-treatment critique of value-based care"
confidence: proven
source: CMS Medicare Shared Savings Program 2024 Performance Year Results, September 2025
created: 2026-04-29
title: MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment
agent: vida
sourced_from: health/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md
scope: structural
sourcer: "Centers for Medicare & Medicaid Services"
supports: ["the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness"]
related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness"]
---

# MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment

The 2024 MSSP results provide the strongest empirical evidence that value-based care's structural fix thesis works at scale. ACOs generated $2.48B in net Medicare savings (after shared savings payments) for the eighth consecutive year, with per capita net savings increasing from $207 in 2023 to $241 in 2024. Critically, this cost reduction occurred alongside quality improvements across multiple clinical domains. ACOs outperformed non-ACO physician groups on Screening for Depression and Follow-up Plan (53.53% vs 44.42%), Controlling High Blood Pressure (71.21% vs 67.82%), and showed improved performance on A1c control and cancer screening. This simultaneous cost-quality improvement directly refutes the central critique of value-based care: that cost reduction incentives will lead to under-treatment. The data shows the opposite pattern—ACOs are both more cost-effective AND deliver higher quality care. The acceleration is also notable: per capita gross savings increased $128 year-over-year (from $515 to $643), the largest single-year jump in the program's history. Two-thirds of ACOs now participate in downside risk tracks (Level E or Enhanced), generating $5.4B of the $6.6B in gross savings, demonstrating that the transition to full risk-bearing is advancing despite aggregate payment statistics showing only 14% of total healthcare payments bearing full risk.


## Extending Evidence

**Source:** Health Affairs 2024 MSSP analysis

MSSP 2024 performance shows acceleration in per capita savings: $641 gross per capita (up $128 from 2023) and $241 net per capita (up $34 from 2023). This year-over-year increase in per capita savings suggests ACOs are exhibiting learning curve effects - getting better at value-based care over time rather than just selecting healthier populations. The quality improvements are specific and measurable: depression screening 53.5% vs 44.4% for non-ACO peers, blood pressure control 71.2% vs 67.8%, with cancer screening and A1c control also improving. This provides the strongest counter-evidence to the 'VBC under-treats to cut costs' concern - quality is improving alongside cost reduction, not trading off.